300, Songdo Bio-daero
Yeonsu-gu
Incheon 21987
South Korea
82 3 2455 3114
https://samsungbiologics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. John Chongbo Rim | CEO, President & Chairman of Board | 3.12B | N/A | 1961 |
Mr. Dong-Joong Kim | CFO, Executive VP, MD & Director | 666M | N/A | 1965 |
Dr. Tae-Han Kim Ph.D. | Executive Director | 2.19B | N/A | 1957 |
Dr. Namjin Chung Ph.D. | Executive VP and Head of Bio R&D Centre & CSO | N/A | N/A | N/A |
Mr. Hyung Woo Moon | Vice President & Head of Legal Compliance Team | N/A | N/A | 1970 |
Mr. James J. Choi | Executive VP, Chief Marketing Officer & Head of Sales Support Center | 569M | N/A | 1967 |
Mr. Yong Park | Vice President, CHRO & Head of HR Support Center | N/A | N/A | 1974 |
Dr. Brian Hosung Min Ph.D. | Executive VP & Head of CDO Development Center | N/A | N/A | N/A |
Mr. Heekyun Lim | VP & Head of Business Consulting Team | N/A | N/A | 1975 |
Dr. Kun Lo Ph.D. | Executive VP & Head of EPCV Center | N/A | N/A | 1963 |
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, Contract Development and Manufacturing Organization Business, and Biopharmaceutical Development and Commercialization Business. It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Samsung Biologics Co.,Ltd.’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder rights: 4; Compensation: 7.